Currently, the reports of JAKi in treating sarcoidosis have primarily used tofacitinib orally, a JAK1/JAK3 inhibitor, or ruxolitinib, a JAK1/JAK2 inhibitor, topically.2 Here, JAK3 is linked to sarcoidosis.